Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF.

Invest New Drugs. 2007 Jun;25(3):265-70. Epub 2006 Dec 5.

PMID:
17146733
2.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS.

J Clin Oncol. 2006 Jul 20;24(21):3451-7.

PMID:
16849761
3.

Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.

Hutson TE, Vukelja S, Atienza D, Awasthi S, Delaune R, Deutsch M, Dien PY, Gregory TF, Kolodziej MJ, Muscato JJ, Raju RN, Ruxer RL Jr, Mull S, Ilegbodu D, Hood K, Nicol S, Berry W.

Invest New Drugs. 2008 Apr;26(2):151-8. doi: 10.1007/s10637-007-9111-2. Epub 2008 Jan 31.

PMID:
18236006
4.

A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.

von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, Chen G, Kania M.

Ann Oncol. 2006 Oct;17(10):1533-8. Epub 2006 Jul 27.

PMID:
16873433
5.

A phase II trial of pemetrexed in patients with metastatic renal cancer.

Thödtmann R, Sauter T, Weinknecht S, Weissbach L, Blatter J, Ohnmacht U, Hanauske A.

Invest New Drugs. 2003 Aug;21(3):353-8.

PMID:
14578684
6.

Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.

Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH.

Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8. doi: 10.1007/s00280-010-1248-6. Epub 2010 Feb 4.

7.

Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.

Llombart-Cussac A, Theodoulou M, Rowland K, Clark RS, Nakamura T, Carrasco E, Cruciani G.

Clin Breast Cancer. 2006 Dec;7(5):380-5.

PMID:
17239262
8.

Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.

Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.

J Clin Oncol. 2003 Apr 15;21(8):1556-61.

PMID:
12697881
9.

Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).

Choi YJ, Lee SH, Lee JL, Ahn JH, Lee KH, You D, Hong B, Hong JH, Ahn H.

Br J Cancer. 2015 Jan 20;112(2):260-5. doi: 10.1038/bjc.2014.591. Epub 2014 Nov 27.

10.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH.

J Clin Oncol. 2006 Feb 1;24(4):552-62. Epub 2006 Jan 3.

PMID:
16391300
11.

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.

Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, de Bono J, Tolcher AW, Patnaik A, Monroe P, Wood L, Schneck KB, Clark R, Rowinsky EK.

Clin Cancer Res. 2007 May 1;13(9):2675-83.

12.

[Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].

Tsuda Y, Kitamura A, Nishimura N, Yagi N, Takayama S, Okafuji K, Tomishima Y, Jinta T, Koyama K, Ohde S, Gotoh K, Chohnabayashi N.

Gan To Kagaku Ryoho. 2015 Apr;42(4):471-5. Japanese.

PMID:
25963695
13.

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.

Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD.

Cancer Chemother Pharmacol. 2006 Apr;57(4):412-26. Epub 2005 Dec 2.

PMID:
16322990
14.

A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.

Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L.

Invest New Drugs. 2008 Aug;26(4):381-6. doi: 10.1007/s10637-008-9124-5. Epub 2008 Feb 28.

PMID:
18305899
15.

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS.

Cancer Chemother Pharmacol. 2011 Aug;68(2):371-8. doi: 10.1007/s00280-010-1493-8. Epub 2010 Oct 27.

PMID:
20978761
16.

A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).

Hattori Y, Iwasaku M, Satouchi M, Nishiyama A, Korogi Y, Otsuka K, Fujita S, Katakami N, Mori M, Nishino K, Morita S, Negoro S.

Jpn J Clin Oncol. 2013 Dec;43(12):1184-9. doi: 10.1093/jjco/hyt159. Epub 2013 Oct 29.

PMID:
24168805
17.
18.

Phase I trials of pemetrexed.

Fossella FV, Gatzemeier U.

Semin Oncol. 2002 Apr;29(2 Suppl 5):8-16. Review.

PMID:
12023787
19.

Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.

Goedhals L, van Wiyk AL, Smith BL, Fourie SJ.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1172-8.

PMID:
16803502
20.

Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.

Socinski MA, Raju RN, Neubauer M, Smith DA, Richards DA, Savin M, Ruxer RL, Reynolds CH, Zhan F, Bromund JL, Chen R, Obasaju C.

J Thorac Oncol. 2008 Nov;3(11):1308-16. doi: 10.1097/JTO.0b013e3181898e32.

Supplemental Content

Support Center